Breast-gynaecological & immuno-oncology international cancer conference (Bgicc) consensus and recommendations for the management of triple-negative breast cancer

Hesham Elghazaly; Hope S. Rugo; Hamdy A. Azim; Sandra M. Swain; Banu Arun; Matti Aapro; Edith A. Perez; Benjamin O. Anderson; Frederique Penault-Llorca; Pierfranco Conte; Nagi S. El Saghir; Cheng Har Yip; Marwan Ghosn; Philip Poortmans; Mohamed A. Shehata; Armando E. Giuliano; Jessica W.T. Leung; Valentina Guarneri; Joseph Gligorov; Bahadir M. Gulluoglu; Hany Abdel Aziz; Mona Frolova; Mohamed Sabry; Charles M. Balch; Roberto Orecchia; Heba M. El-Zawahry; Sana Al-Sukhun; Khaled Abdel Karim; Alaa Kandil; Ruslan M. Paltuev; Meteb Foheidi; Mohamed El-Shinawi; Manal Elmahdy; Omalkhair Abulkhair; Wentao Yang; Adel T. Aref; Joaira Bakkach; Nermean Bahie Eldin; Hagar Elghazawy

doi:10.3390/cancers13092262

Breast-gynaecological & immuno-oncology international cancer conference (Bgicc) consensus and recommendations for the management of triple-negative breast cancer

Hesham Elghazaly, Hope S. Rugo, Hamdy A. Azim, Sandra M. Swain, Banu Arun, Matti Aapro, Edith A. Perez, Benjamin O. Anderson, Frederique Penault-Llorca, Pierfranco Conte, Nagi S. El Saghir, Cheng Har Yip, Marwan Ghosn, Philip Poortmans, Mohamed A. Shehata, Armando E. Giuliano, Jessica W.T. Leung, Valentina Guarneri, Joseph Gligorov, Bahadir M. GulluogluHany Abdel Aziz, Mona Frolova, Mohamed Sabry, Charles M. Balch, Roberto Orecchia, Heba M. El-Zawahry, Sana Al-Sukhun, Khaled Abdel Karim, Alaa Kandil, Ruslan M. Paltuev, Meteb Foheidi, Mohamed El-Shinawi, Manal Elmahdy, Omalkhair Abulkhair, Wentao Yang, Adel T. Aref, Joaira Bakkach, Nermean Bahie Eldin, Hagar Elghazawy

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Background: The management of patients with triple-negative breast cancer (TNBC) is challenging with several controversies and unmet needs. During the 12th Breast-Gynaecological & Immuno-oncology International Cancer Conference (BGICC) Egypt, 2020, a panel of 35 breast cancer experts from 13 countries voted on consensus guidelines for the clinical management of TNBC. The consensus was subsequently updated based on the most recent data evolved lately. Methods: A consensus conference approach adapted from the American Society of Clinical Oncology (ASCO) was utilized. The panellists voted anonymously on each question, and a consensus was achieved when ≥75% of voters selected an answer. The final consensus was later circulated to the panellists for critical revision of important intellectual content. Results and conclusion: These recommendations represent the available clinical evidence and expert opinion when evidence is scarce. The percentage of the consensus votes, levels of evidence and grades of recommendation are presented for each statement. The consensus covered all the aspects of TNBC management starting from defining TNBC to the management of metastatic disease and highlighted the rapidly evolving landscape in this field. Consensus was reached in 70% of the statements (35/50). In addition, areas of warranted research were identified to guide future prospective clinical trials.

Original language	English (US)
Article number	2262
Journal	Cancers
Volume	13
Issue number	9
DOIs	https://doi.org/10.3390/cancers13092262
State	Published - May 1 2021

Keywords

BRCA mutations
Consensus
Immunotherapy
Platinum
Triple-negative breast cancer

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.3390/cancers13092262

Cite this

Elghazaly, H., Rugo, H. S., Azim, H. A., Swain, S. M., Arun, B., Aapro, M., Perez, E. A., Anderson, B. O., Penault-Llorca, F., Conte, P., El Saghir, N. S., Yip, C. H., Ghosn, M., Poortmans, P., Shehata, M. A., Giuliano, A. E., Leung, J. W. T., Guarneri, V., Gligorov, J., ... Elghazawy, H. (2021). Breast-gynaecological & immuno-oncology international cancer conference (Bgicc) consensus and recommendations for the management of triple-negative breast cancer. Cancers, 13(9), Article 2262. https://doi.org/10.3390/cancers13092262

Elghazaly, H, Rugo, HS, Azim, HA, Swain, SM, Arun, B, Aapro, M, Perez, EA, Anderson, BO, Penault-Llorca, F, Conte, P, El Saghir, NS, Yip, CH, Ghosn, M, Poortmans, P, Shehata, MA, Giuliano, AE, Leung, JWT, Guarneri, V, Gligorov, J, Gulluoglu, BM, Aziz, HA, Frolova, M, Sabry, M, Balch, CM, Orecchia, R, El-Zawahry, HM, Al-Sukhun, S, Karim, KA, Kandil, A, Paltuev, RM, Foheidi, M, El-Shinawi, M, Elmahdy, M, Abulkhair, O, Yang, W, Aref, AT, Bakkach, J, Eldin, NB & Elghazawy, H 2021, 'Breast-gynaecological & immuno-oncology international cancer conference (Bgicc) consensus and recommendations for the management of triple-negative breast cancer', Cancers, vol. 13, no. 9, 2262. https://doi.org/10.3390/cancers13092262

@article{d6ea9e55ce424e87ab703278d6aa884e,

title = "Breast-gynaecological & immuno-oncology international cancer conference (Bgicc) consensus and recommendations for the management of triple-negative breast cancer",

abstract = "Background: The management of patients with triple-negative breast cancer (TNBC) is challenging with several controversies and unmet needs. During the 12th Breast-Gynaecological & Immuno-oncology International Cancer Conference (BGICC) Egypt, 2020, a panel of 35 breast cancer experts from 13 countries voted on consensus guidelines for the clinical management of TNBC. The consensus was subsequently updated based on the most recent data evolved lately. Methods: A consensus conference approach adapted from the American Society of Clinical Oncology (ASCO) was utilized. The panellists voted anonymously on each question, and a consensus was achieved when ≥75% of voters selected an answer. The final consensus was later circulated to the panellists for critical revision of important intellectual content. Results and conclusion: These recommendations represent the available clinical evidence and expert opinion when evidence is scarce. The percentage of the consensus votes, levels of evidence and grades of recommendation are presented for each statement. The consensus covered all the aspects of TNBC management starting from defining TNBC to the management of metastatic disease and highlighted the rapidly evolving landscape in this field. Consensus was reached in 70% of the statements (35/50). In addition, areas of warranted research were identified to guide future prospective clinical trials.",

keywords = "BRCA mutations, Consensus, Immunotherapy, Platinum, Triple-negative breast cancer",

author = "Hesham Elghazaly and Rugo, {Hope S.} and Azim, {Hamdy A.} and Swain, {Sandra M.} and Banu Arun and Matti Aapro and Perez, {Edith A.} and Anderson, {Benjamin O.} and Frederique Penault-Llorca and Pierfranco Conte and {El Saghir}, {Nagi S.} and Yip, {Cheng Har} and Marwan Ghosn and Philip Poortmans and Shehata, {Mohamed A.} and Giuliano, {Armando E.} and Leung, {Jessica W.T.} and Valentina Guarneri and Joseph Gligorov and Gulluoglu, {Bahadir M.} and Aziz, {Hany Abdel} and Mona Frolova and Mohamed Sabry and Balch, {Charles M.} and Roberto Orecchia and El-Zawahry, {Heba M.} and Sana Al-Sukhun and Karim, {Khaled Abdel} and Alaa Kandil and Paltuev, {Ruslan M.} and Meteb Foheidi and Mohamed El-Shinawi and Manal Elmahdy and Omalkhair Abulkhair and Wentao Yang and Aref, {Adel T.} and Joaira Bakkach and Eldin, {Nermean Bahie} and Hagar Elghazawy",

note = "Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2021",

month = may,

day = "1",

doi = "10.3390/cancers13092262",

language = "English (US)",

volume = "13",

journal = "Cancers",

issn = "2072-6694",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "9",

}

TY - JOUR

T1 - Breast-gynaecological & immuno-oncology international cancer conference (Bgicc) consensus and recommendations for the management of triple-negative breast cancer

AU - Elghazaly, Hesham

AU - Rugo, Hope S.

AU - Azim, Hamdy A.

AU - Swain, Sandra M.

AU - Arun, Banu

AU - Aapro, Matti

AU - Perez, Edith A.

AU - Anderson, Benjamin O.

AU - Penault-Llorca, Frederique

AU - Conte, Pierfranco

AU - El Saghir, Nagi S.

AU - Yip, Cheng Har

AU - Ghosn, Marwan

AU - Poortmans, Philip

AU - Shehata, Mohamed A.

AU - Giuliano, Armando E.

AU - Leung, Jessica W.T.

AU - Guarneri, Valentina

AU - Gligorov, Joseph

AU - Gulluoglu, Bahadir M.

AU - Aziz, Hany Abdel

AU - Frolova, Mona

AU - Sabry, Mohamed

AU - Balch, Charles M.

AU - Orecchia, Roberto

AU - El-Zawahry, Heba M.

AU - Al-Sukhun, Sana

AU - Karim, Khaled Abdel

AU - Kandil, Alaa

AU - Paltuev, Ruslan M.

AU - Foheidi, Meteb

AU - El-Shinawi, Mohamed

AU - Elmahdy, Manal

AU - Abulkhair, Omalkhair

AU - Yang, Wentao

AU - Aref, Adel T.

AU - Bakkach, Joaira

AU - Eldin, Nermean Bahie

AU - Elghazawy, Hagar

PY - 2021/5/1

Y1 - 2021/5/1

N2 - Background: The management of patients with triple-negative breast cancer (TNBC) is challenging with several controversies and unmet needs. During the 12th Breast-Gynaecological & Immuno-oncology International Cancer Conference (BGICC) Egypt, 2020, a panel of 35 breast cancer experts from 13 countries voted on consensus guidelines for the clinical management of TNBC. The consensus was subsequently updated based on the most recent data evolved lately. Methods: A consensus conference approach adapted from the American Society of Clinical Oncology (ASCO) was utilized. The panellists voted anonymously on each question, and a consensus was achieved when ≥75% of voters selected an answer. The final consensus was later circulated to the panellists for critical revision of important intellectual content. Results and conclusion: These recommendations represent the available clinical evidence and expert opinion when evidence is scarce. The percentage of the consensus votes, levels of evidence and grades of recommendation are presented for each statement. The consensus covered all the aspects of TNBC management starting from defining TNBC to the management of metastatic disease and highlighted the rapidly evolving landscape in this field. Consensus was reached in 70% of the statements (35/50). In addition, areas of warranted research were identified to guide future prospective clinical trials.

AB - Background: The management of patients with triple-negative breast cancer (TNBC) is challenging with several controversies and unmet needs. During the 12th Breast-Gynaecological & Immuno-oncology International Cancer Conference (BGICC) Egypt, 2020, a panel of 35 breast cancer experts from 13 countries voted on consensus guidelines for the clinical management of TNBC. The consensus was subsequently updated based on the most recent data evolved lately. Methods: A consensus conference approach adapted from the American Society of Clinical Oncology (ASCO) was utilized. The panellists voted anonymously on each question, and a consensus was achieved when ≥75% of voters selected an answer. The final consensus was later circulated to the panellists for critical revision of important intellectual content. Results and conclusion: These recommendations represent the available clinical evidence and expert opinion when evidence is scarce. The percentage of the consensus votes, levels of evidence and grades of recommendation are presented for each statement. The consensus covered all the aspects of TNBC management starting from defining TNBC to the management of metastatic disease and highlighted the rapidly evolving landscape in this field. Consensus was reached in 70% of the statements (35/50). In addition, areas of warranted research were identified to guide future prospective clinical trials.

KW - BRCA mutations

KW - Consensus

KW - Immunotherapy

KW - Platinum

KW - Triple-negative breast cancer

UR - http://www.scopus.com/inward/record.url?scp=85105403112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85105403112&partnerID=8YFLogxK

U2 - 10.3390/cancers13092262

DO - 10.3390/cancers13092262

M3 - Article

C2 - 34066769

AN - SCOPUS:85105403112

SN - 2072-6694

VL - 13

JO - Cancers

JF - Cancers

IS - 9

M1 - 2262

ER -

Breast-gynaecological & immuno-oncology international cancer conference (Bgicc) consensus and recommendations for the management of triple-negative breast cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this